Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and ...
Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies
Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials. Read why CRBP stock is ...
We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. Indeed, Corbus Pharmaceuticals Holdings ( NASDAQ:CRBP) stock is up 478% in the last year, providing strong gains for ...
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors despite daily gains
Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 1.40% to $18.78 Friday, on what proved to be an all-around great ...
Corbus Pharmaceuticals Reports Q3 2024 Financials and Updates
Corbus Pharmaceuticals Holdings ( (CRBP) ) has released its Q3 earnings. Here is a breakdown of the information Corbus Pharmaceuticals Holdings ...
Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update
Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701 ...